Kinetic aspects of misonidazole and its major metabolite in radiotherapy.
Oral doses of misonidazole between 0.75 and 1.3 g/m2 were administered during 3-5 days per week to 21 patients with various malignancies. Mean plasma levels of misonidazole and desmethylmisonidazole at the times of radiotherapy were in the range 20-50 and 2-12 mg/l respectively. Slight accumulation of misonidazole and desmethylmisonidazole in plasma was observed with a dosage interval of 24 h. In patients with anticonvulsant comedication plasma elimination half-lives of misonidazole of 4.1-8.9 h were found. Observed side-effects were nausea and vomiting (9%), exanthema or rashes (14%) and mild peripheral neuropathy (9%).
D000328:Adult; D000368:Aged; D005260:Female; D006207:Half-Life; D006801:Humans; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D008920:Misonidazole / Q000009:adverse effects / Q000031:analogs & derivatives / Q000097:blood / Q000378:metabolism* / Q000627:therapeutic use; D009369:Neoplasms / Q000378:metabolism / Q000532:radiotherapy*; D009593:Nitroimidazoles / Q000097:blood / Q000378:metabolism*
D009593:Nitroimidazoles; D008920:Misonidazole; C009997:desmethylmisonidazole